Synthesis and Characterization of Chitosan-Polyvinyl Alcohol Blended with Cloisite 30B for Controlled Release of the Anticancer Drug Curcumin

Abstract

In the present research program, polymer nanocomposites have been used as the drug carrier for delivery systems of anticancer drug. Chitosan (Cs) and Polyvinyl Alcohol (PVA) with different ratios were blended with different wt% of Cloisite 30B solution by solvent casting method. Glutaraldehyde with different wt% was added to the blended solution as a crosslinking agent. Cloisite 30B was incorporated in the formulation as a matrix material component which also plays the role of a co-emulsifier in the nanocomposite preparation. Curcumin with different concentrations were loaded with CS-PVA/ C 30B nanocomposites for studying the in-vitro drug delivery systems. Morphology and structure characterization of nanocomposites were investigated by fourier transmission infra red spectroscopy (FTIR), scanning electron microscope (SEM), tensile strength and water uptake capacity. The drug release was studied by changing time, pH and drug concentrations. The kinetics of the drug release was studied in order to ascertain the type of release mechanism. Based on the diffusion as well as the kinetics, the mechanism of the drug release from the composite matrix has been reported.

Share and Cite:

U. Parida, A. Nayak, B. Binhani and P. Nayak, "Synthesis and Characterization of Chitosan-Polyvinyl Alcohol Blended with Cloisite 30B for Controlled Release of the Anticancer Drug Curcumin," Journal of Biomaterials and Nanobiotechnology, Vol. 2 No. 4, 2011, pp. 414-425. doi: 10.4236/jbnb.2011.24051.

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1] D. Sahoo, S. Sahoo, P. Mohanty, S. Sasmal, P.L. Nayak, “Chitosan: a new versatile biopolymer for various applications, ” Designed Monomers and Polymers, Vol. 12, 2009, 377-404,.
[2] S. Sahoo, A. Sasmal, R. Nanda, A.R. Phani, P.L. Nayak, “Synthesis of chitosan-poly bhisek Sasmal, caprolactone blend for control delivery of ofloxacin drug,” Carbohydrate Polymers, Vol. 79, 2010,106-113.
[3] S.K. Mallapragada, N.A. Peppas, “Dissolution mechanism of semicrystalline poly (vinyl alcohol) in water,” J Polym Sci: Part B, Polym. Physics Vol. 34, 1996, 1339- 1349.
[4] G. Paradossi, R. Lisi, M. Paci, V. Crescenzi, “New hydrogels based on poly (vinyl alcohol),” J. Polym Sci., Part A , Polym. Chem, Vol. 34, 1996, 3417-3495.
[5] J. Jegal, K. Lee, “Nanofilteration membranes based on poly (vinyl alcohol) and ionic polymers,” J Appl Polym. Sci, Vol. 72, 1999, 1755-1762.
[6] T. Chandy, C.P. Sharma, “Prostaglandin E1- immobilized poly (vinyl alcohol) -blended chitosan membranes: Blood compatibility and permeability properties,” J Appl. Polym. Sci, Vol. 44, 1992, 2145-2156.
[7] J. Mathew, M. Kodama, “Study of blood compatible polymers I. modification of poly (vinyl alcohol),” Polym. J , Vol. 24, 1992, 31- 41.
[8] U. Edlund, & A.C. Albertsson, “Degradable Polymer Microspheres for Controlled Drug Delivery,” Advances in Polymer Science, Vol. 157, 2002, 67-112.
[9] A. Rajeev Jain, “The manufacturing techniques of various drug loaded biodegradable poly(lactide-co-glycolide) (PLGA) devices,” Biomaterials, Vol. 21, 2000, 2475.
[10] K.R. Kamath and K. Park, “Biodegradable hydrogels in drug delivery,” Advanced Drug Delivery Reviews, Vol. 11, 1993, 59-84.
[11] A.G. Mikos, M.D. Lyman, L.E. Freed, & R. Langer, “Wetting of poly(L-lactic acid) and poly (DL-lactic-co- glycolic acid) foams for tissue culture,” Biomaterials, Vol. 15(1), 1994, 55-58.
[12] H.S. Kas, “Chitosan: properties, preparation and application to microparticulate systems,” Journal of Microencapsulation , Vol. 14 (6), 1997, 689-711.
[13] T. Chandy & C.P. Sharma, “Chitosan as a biomaterial, Artificial Cells, Blood Substitutes,” Biotechnology: An International Journal, Vol. 18, 1990, 1-24.
[14] H. Fukuda, “Polyelectrolyte Complexes of Chitosan with Sodium Carboxymethylcellulose,” Bulletin of the Chemi- cal Society of Japan, Vol. 53 (4), 1980, 837-840.
[15] Y. Kato, H. Onishi, & Y. Machida, “Application of chitin and chitosan derivatives in the pharmaceutical field,” Current Pharmaceutical Biotechnology, Vol. 4, 2003, 303-309.
[16] B. Gibbs Jackson, “Mechanism-Based Target Identifica- tion and Drug Discovery in Cancer Research,” Science, Vol. 287, 2000, 1969-1973.
[17] P. Mankad, J. Spatenka, Z. Slavik, G. Oneil, A. Chester, & M. Yacoub, “Acute Effects of Cyclosporine and Cr EL on Endothelial Function and Vascular Smooth Muscle in the Isolated Rat-Heart,” Cardiovascular Drugs and Therapy, Vol. 6(1), 1992, 77-83.
[18] T. M. Aminabhavi, & H. G. Naik, “Chemical compatibility study of geomembranes-sorption/desorption, diffusion and swelling phenomena,” Journal of Hazardous Materials, Vol. 60, 1998, 175-203.
[19] D. Sahoo, S. Sahoo, J. Das, T.K. Dangar, P.L. Nayak., “Antibacterial Activity of chitosan crosslinked with Aldehydes and blended with Cloisite 30B,” NanoTrends , Vol 10, 2011, 01-09.
[20] T. Sekine, K. Yoshida, F. Matsuzaki, T. Yanaki, & M. Yamaguchi, “A novel method for preparing oil-in water- in-oil type multiple emulsions using organophilic montmorillonite clay mineral,” Journal of Surfactants and Detergents, Vol 2 (3), 1999, 309-15.
[21] A. Goel, B.A. Kunnumakkara, B.B. Aggarwal, “Curcu- min as “Curecumin”from kitchen to clinic (commentary),” Biochem Pharmacol, Vol 75, 2008, 787-809.
[22] M.N. Sreejayan Rao, “Nitric oxide scanvenging by curcuminoids,” J Pharm Pharmacol, Vol 49, 1997, 105-107.
[23] H.P. Ammon, M.A. Wahl, “Pharmacology of Curcuma longa,” Planta Med, Vol 57, 1991, 1-7.
[24] I. Brouet, H. Ohshima, “Curcumin, An anti-tumour pro- moter and antiimflammatory agent, inhibits induction of nitric oxide synthase in activated macrophages,” Biochem Biophys Res Commun, Vol 206, 1995, 533-40.
[25] M. Dikshit, L. Rastogi, R. Shukla, R.C. Srimal, “Preven- tion of ischaemiainduced biochemical changes by curcumin and quinidine in the cat heart,” Ind J Med Res, Vol 101, 1995, 31-50.
[26] M.M. Yallapu, M. Jaggi and S.C.Chauhan, “β-Cyclodex- trin-curcumin self-assembly enhances curcumin delivery in prostate cancer cells Original Research Article,” Colloids and Surfaces B: Biointerfaces, Vol. 79, 2010, 113- 125.
[27] K.Varaprasad, Y. M.Mohan, K. Vimala and K. M. Raju, “Synthesis and characterization of hydrogel-silver nano- particle-curcumin composites for wound dressing and an- tibacterial application,” Journal of Applied Polymer Sci- ence, Vol. 121, 2011, 784-796.
[28] C.V. Rao, A. Rivenson, B. Simi, B.S. Reddy, “Chemo- prevention of colon carcinogenesis by dietary curcumin, a naturally occurring plant phenolic compound,” Cancer Res, Vol 55, 1995, 259-266.
[29] Y. Kiso, Y. Suzuki, N. Watanabe, Y. Oshima, H. Hikino, “Antihepatotoxic principles of Curcuma longa rhizomes,” Planta Med, Vol 49, 1983, 185-187.
[30] H.H. Tonnesen, J. Karlsen, “Studies on curcumin and curcuminoids. VI. Kinetics of curcumin degradation in aqueous solution,” Z Lebensm Unters Forsch, Vol 180, 1985, 402-404.
[31] A. Kunwar, A. Barik, R. Pandey, K.I. Priyadarsini, “Transport of liposomal and albumin loaded curcumin to living cells; an absorption and fluorescence spectroscopic study,” Biochim Biophys Acta, Vol 1760, 2006, 1513- 1520.
[32] K. Vidyalakshmi K. N. Rashmi, T. M. Pramod Kumar, Siddaramaiah, “Studies on Formulation and In Vitro Evaluation of PVA/Chitosan Blend Films for Drug Delivery,” Journal of Macromolecular Science w Part A—Pure and Applied Chemistry, Vol. A41, 2004, 1115- 1122.
[33] K. Vimala, Y. M. Mohan, K.Varaprasad, N. N. Redd, S. Ravindra, N.S.Naidu, K.M.Raju, Fabrication of Cur- cumin Encapsulated Chitosan-PVA Silver Nanocompo- site Films for Improved Antimicrobial Activity,” Journal of Biomaterials and Nanobiotechnology, Vol. 2, 2011, 55-64.
[34] M.M. Yallapu, B.K. Gupta, M. Jaggi and S.C.Chauhan, “Fabrication of curcumin encapsulated PLGA nanoparti- cles for improved therapeutic effects in metastatic cancer cells Original Research Article,” Journal of Colloid and Interface Science, Vol. 351, 2010, 19-29.
[35] G. Xu, & H. Sunada, “Influence of Formation changes on drug release kinetics,” Chemical & Pharmaceutical Bulletin, Vol 43, 1995, 483-487.
[36] T. Higuchi, “Mechanism of sustained action medication. Theoretical analysis of rate of release of solid drugs dispersed in solid matrices,” Journal of Pharmaceutical Sciences, Vol 52 (12), 1963, 1145-1149.
[37] A. R. Kulkarni, K. S. Soppimath, & T. M. Aminabhavi, “Controlled release of diclofenac sodium from sodium alginate beads crosslinked with glutaraldehyde,” Phramaceutica Acta Helvitae , Vol. 74, 1999, 29-36.
[38] R. L. Ritger, & N.A. Peppas, “A simple equation for dis- position of solute release-II,” Journal of Controlled Release, Vol. 5, 1987, 37-42.
[39] A.K. Singla, A. Garg & D. Aggarwal, “Paclitaxel and its formulations,” International Journal of Pharmaceutics, Vol. 235 (1), 2002, 179-192.
[40] A.K. Singla, & M. Chawla, “Chitosan: some pharmaceutical and biological aspects—an update,” Journal of Pharmacy and Pharmacology, Vol. 53 (8), 2001, 1047- 1067.

Copyright © 2024 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.